SPRY2 and prostate carcinoma: In many instances, SPRY2 isoform is downregulated, suggesting a possible tumor suppressor function in chronic lymphocytic leukemia CLL [7], non-small cell lung cancer NSCLC [8], hepatocellular carcinoma [9], breast cancer [10], and prostate cancer [11].